Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...

The addition of the linker should not induce aggregation and needs to ensure acceptable PK characteristics, while limiting the premature release of the payload in plasma and enabling the effective ...

In this free webinar, explore recent developments in next-generation antibody-drug conjugates (ADCs) and emerging strategies in ADC conjugation and linker design. Attendees will learn how ...

ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies ...

This collection of articles and expert perspectives explores the critical challenges shapingADC development today, from ...

Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field, showing how they are being used as key levers for ADC drug developers to ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates (ADC) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class ...

Ideally, anti-cancer treatments should specifically target and kill tumour cells while leaving normal, healthy tissues relatively unscathed. The therapeutic ratio of the maximum tolerated to the ...

ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution ...